1. Home
  2. PCLA vs BOLD Comparison

PCLA vs BOLD Comparison

Compare PCLA & BOLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo PicoCELA Inc. American Depositary Shares

PCLA

PicoCELA Inc. American Depositary Shares

HOLD

Current Price

$6.05

Market Cap

58.6M

ML Signal

HOLD

Logo Boundless Bio Inc.

BOLD

Boundless Bio Inc.

HOLD

Current Price

$2.38

Market Cap

60.8M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
PCLA
BOLD
Founded
2008
2018
Country
Japan
United States
Employees
N/A
N/A
Industry
Building Products
Sector
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
58.6M
60.8M
IPO Year
2024
2024

Fundamental Metrics

Financial Performance
Metric
PCLA
BOLD
Price
$6.05
$2.38
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
19.0K
★ 199.4K
Earning Date
02-12-2027
11-04-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 32.47
EPS
★ N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
★ N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.12
$0.96
52 Week High
$19.61
$3.16

Technical Indicators

Market Signals
Indicator
PCLA
BOLD
Relative Strength Index (RSI) 42.64 37.70
Support Level $5.94 $1.40
Resistance Level $7.83 $2.71
Average True Range (ATR) 0.37 0.16
MACD -0.03 -0.01
Stochastic Oscillator 31.45 25.58

Price Performance

Historical Comparison
PCLA
BOLD

About PCLA PicoCELA Inc. American Depositary Shares

PicoCELA Inc specializes in manufacturing, installing, and servicing enterprise wireless mesh solutions. The company generates revenue from two main sources: product equipment sales, and Software as a Service (SaaS) and maintenance services. The company develops the PCWL series of mesh Wi-Fi access points, which utilize its proprietary PicoCELA Backhaul Engine (PBE) technology to enable wireless communication. The company outsources manufacturing and sells these devices directly to customers through distributors. Additionally, the company offers a cloud portal service in a SaaS model, allowing users to monitor connectivity and traffic at their access points. This platform also supports the installation of proprietary edge-computing software into the devices.

About BOLD Boundless Bio Inc.

Boundless Bio Inc is a clinical-stage oncology company. It is focused on developing cancer therapeutics that address the unmet need in patients with oncogene-amplified tumors by targeting extrachromosomal DNA (ecDNA), a root cause of oncogene amplification observed in cancer patients. Using its proprietary Spyglass platform, the company identifies targets essential for ecDNA functionality, then designs and develops small-molecule drugs called ecDNA-directed therapies (ecDTx) to inhibit those targets. Its main ecDTx candidate under development, BBI-940, is a novel, oral, selective degrader that has demonstrated potent anti-tumor activity across a range of cancer cell lines and mouse xenograft models, including single-agent tumor regressions.

Share on Social Networks: